gp130/CD130 Antibody (29104) [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Glycoprotein 130 (gp130; also known as IL-6 signal transducer, IL-6 receptor beta, oncostatin-M alpha subunit) is a ubiquitously expressed, 130 kDa type I transmembrane glycoprotein and member of the type II subfamily, type I cytokine receptor family. Functionally, it is responsible for transduction of the IL-6 signal across the plasma membrane (1). Rat gp130 is synthesized as a 918 amino acid (aa) precursor with a 22 aa signal sequence, a 596 aa extracellular domain (ECD), a 22 aa transmembrane region, and a 278 aa cytoplasmic tail. Eleven potential N-linked glycosylation sites are found within the rat gp130 ECD (1). The ECD also contains an N terminal immunoglobulin (Ig)-like C2-type domain, followed by the cytokine receptor homology region (CHR) which is made up of two fibronectin type III-like domains and a WSXWS motif, and three additional fibronectin type III-like domains (2). The domains in the CHR are the structural hallmarks of the hematopoietic cytokine receptor family (2). Human gp130 shares 73% and 79% aa sequence identity with mouse and rat gp130, respectively. Gp130 serves as the signal transducing receptor subunit for the IL-6-type cytokines consisting of interleukin (IL)-6, IL-11, leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), new neurotrophin factor-1 (NNT-1), IL-27, cardiotrophin-1 (CT-1), and cardiotrophin like cytokine (CLC) (2 - 5). These cytokines are involved in a variety of functions including the modulation of inflammatory and immune responses, heart development, fertility, and many other activities (2).

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 2 confirmed species: Human, Mouse.

We have publications tested in 2 applications: ICC, Western Blot.

Showing Publications 1 - 5 of 5.

Publications using MAB2281	Applications	Species
Karavyraki M, Porter RK. Evidence of a role for interleukin-6 in anoikis resistance in oral squamous cell carcinoma Medical Oncology 4/29/2022 [PMID: 35484352]
H Wang, W Hou, A Perera, C Bettler, JR Beach, X Ding, J Li, MF Denning, A Dhanarajan, SJ Cotler, C Joyce, J Yin, F Ahmed, LR Roberts, W Qiu Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling Cell Reports, 2021-02-23;34(8):108765. 2021-02-23 [PMID: 33626345] (ICC, Western Blot, Human)	ICC, Western Blot	Human
Y Hosokawa, I Hosokawa, K Ozaki, T Matsuo IL-27 Modulates Chemokine Production in TNF-? -Stimulated Human Oral Epithelial Cells Cell. Physiol. Biochem., 2017-10-05;43(3):1198-1206. 2017-10-05 [PMID: 28977795] (Western Blot, Human)	Western Blot	Human
Campbell I, Erta M, Lim S, Frausto R, May U, Rose-John S, Scheller J, Hidalgo J Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci, 2014-02-12;34(7):2503-13. 2014-02-12 [PMID: 24523541] (Western Blot, Mouse)	Western Blot	Mouse
Ammit AJ, Moir LM, Oliver BG, Hughes JM, Alkhouri H, Ge Q, Burgess JK, Black JL, Roth M Effect of IL-6 trans-signaling on the pro-remodeling phenotype of airway smooth muscle. Am. J. Physiol. Lung Cell Mol. Physiol., 2006-08-25;292(1):L199-206. 2006-08-25 [PMID: 16936245] (Western Blot, Human)	Western Blot	Human

Array MAB2281

• gp130/CD130 Antibodies
• gp130/CD130 Antibody Pair
• gp130/CD130 ELISA Kits
• gp130/CD130 Lysate
• gp130/CD130 Protein
• gp130/CD130 ELISAs
• gp130/CD130 Proteins and Enzymes